Meeting
2023 ASCO Genitourinary Cancers Symposium
Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
Authors
Daniel J. George
Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC
Daniel J. George , Nasreen Khan , Niculae Constantinovici , Javeed Khan , Guifang Chen , Julie Xu , Jorge A. Ortiz , Alicia K. Morgans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 332)
DOI
10.1200/JCO.2023.41.6_suppl.332
Abstract #
332
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.
First Author: Benjamin H Lowentritt
Poster
2021 ASCO Annual Meeting
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.
First Author: Karim Fizazi
Poster
2021 Genitourinary Cancers Symposium
Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).
First Author: Richard Gagnon